Solriamfetol 150 MG
SOL-MDD-302
Phase 3 small_molecule active
Quick answer
Solriamfetol 150 MG for Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms is a Phase 3 program (small_molecule) at Axsome Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Axsome Therapeutics
- Indication
- Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active